secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2022-06-08T23:59:59+00:00
Accession:  0001193125-22-170277
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Therapeutics fails to regain Nasdaq bid price compliance; granted extension to Dec 5, 2022
--------------------------------------------------------------------------------

- Received deficiency notice Dec 2021 for bid price below $1.00; initial 180-day period ended June 6, 2022 without compliance.
- Nasdaq granted additional 180-day period until Dec 5, 2022 to cure, conditional on meeting other listing requirements.
- Company intends to cure deficiency by effecting a reverse stock split if necessary.
- If compliance not achieved by Dec 5, 2022, Nasdaq will issue delisting notification; Company may appeal to Listing Qualifications Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522170277/0001193125-22-170277-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312522170277/d368711d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-170277

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer